We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




RNA Blood Test Detects Cancers and Resistance to Treatment

By LabMedica International staff writers
Posted on 22 Apr 2025

A newly developed blood test offers the ability to detect cancer, understand how cancer resists treatments, and assess tissue damage from non-cancerous conditions. More...

This innovative test, created by researchers at Stanford Medicine (Stanford, CA, USA), analyzes RNA molecules found in the bloodstream. Known as cell-free RNA, these molecules are fragments that no longer reside within cells. Blood contains natural byproducts of cell death from various tissues and organs, including cancerous tumors, in the form of both DNA and RNA fragments. After over six years of research, the team developed new techniques to focus on messenger RNA in blood, which they used to identify cancer at different stages, track resistance to treatments, and monitor healthy tissue injury.

Cell-free RNA is present in very small quantities in blood, with around 95% being ribosomal RNA that forms cellular structures responsible for protein synthesis. The new test specifically analyzes messenger RNA, which makes up less than 5% of the total cell-free RNA pool, as these molecules provide a signal about which genes are being expressed as proteins. A paper detailing the methodology and potential uses of this cell-free RNA blood test was published in Nature. The researchers focused their analysis on around 5,000 genes that are typically not found in the blood of healthy individuals, referred to as rare abundance genes. By concentrating on these genes, the test's ability to accurately detect cancer was increased by more than 50 times. The test identified lung cancer RNA in 73% of lung cancer patients, even at early stages. By detecting cell-free messenger RNA, the blood test is able to monitor conditions that don’t rely on the genetic mutations detected by traditional DNA-based tests, such as identifying resistance mechanisms to cancer treatments.

The team also faced a challenge in eliminating the influence of platelets, which contain RNA but no DNA and are responsible for clotting. To address this, the researchers developed a combination of molecular and computational techniques that filter out the effects of platelets, ensuring clearer signals from cancer. This method works not only on fresh blood samples but also on samples that have been stored previously. Beyond cancer detection, the new cell-free RNA method has shown promise in non-cancer applications. It successfully detected elevated levels of normal lung RNA in the blood of patients with acute respiratory distress syndrome (ARDS), a condition that severely damages the lungs and leads to cell death. Additionally, normal lung RNA levels in blood samples from COVID-19 patients correlated with the severity of their illness. The test also found normal lung RNA in the blood of healthy smokers, possibly indicating subtle lung damage caused by smoking.

“Just as archeologists can learn about ancient societies by studying the garbage they left behind, we can learn a lot about what is going on in the cells of a patient’s body based on the degraded RNA molecules that are cleared through the blood,” said co-lead author Maximilian Diehn, MD, PhD, and the Jack, Lulu, and Sam Willson Professor and a Stanford Medicine professor of radiation oncology. “We have developed a sensitive, versatile new type of liquid biopsy that measures cell-free and circulating-tumor RNA and has the potential to enhance personalized medicine in cancer and non-cancer diseases.”

“Unfortunately, a significant fraction of our patients who are being treated for cancer go on to have their therapy stop working, and that resistance is often based on adaptations that do not involve genetic changes, but instead altering how the cells behave or even how the cells look under a microscope,” added Ash Alizadeh, MD, PhD, the Moghadam Family Professor and a professor of medicine, oncology and hematology, who co-led the study with Diehn. “Our non-invasive approach has the potential of avoiding surgical biopsies and identifying these common types of resistance earlier before substantial disease burden shows up on scans or presents with symptoms like pain, providing an earlier opportunity to change treatment and improve outcomes.”


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.